Female Hormones and Liver Cancer Risk
Author Information
Author(s): A. Tavani, E. Negri, F. Parazzini, S. Franceschi, C. La Vecchia
Primary Institution: Istituto di Ricerche Farmacologiche 'Mario Negri'
Hypothesis
Is there a relationship between female hormone use and the risk of hepatocellular carcinoma?
Conclusion
The study found that oral contraceptive use is associated with an increased risk of hepatocellular carcinoma, which persists for over 10 years after stopping use.
Supporting Evidence
- Oral contraceptive users had a relative risk of 2.6 for liver cancer compared to non-users.
- The risk increased with the duration of oral contraceptive use.
- The risk persisted for more than 10 years after stopping oral contraceptive use.
- Evidence suggests that oestrogen replacement therapy does not significantly increase liver cancer risk.
Takeaway
Using birth control pills might make women more likely to get liver cancer, even years after they stop using them.
Methodology
A case-control study was conducted with 82 female liver cancer cases and 368 controls, analyzing hormone use and cancer risk.
Potential Biases
The study design minimizes selection, information, and confounding bias.
Limitations
The study is hospital-based, which may limit generalizability, and did not measure hepatitis B serum markers.
Participant Demographics
Participants were women aged 26-76, with a median age of 59 years.
Statistical Information
P-Value
p<0.05
Confidence Interval
95% CI 1.0-7.0
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website